Oncoinfluencers to Follow on Social Media: Dr. Hagop Kantarjian

We are excited to feature Dr. Hagop Kantarjian, a distinguished figure in Hematology/Oncology, as our next oncoinfluencer.

Dr. Kantarjian is active on X/Twitter, where he shares a wealth of information on leukemia. His posts include updates on translational-clinical developmental therapeutics, advancements in treatment, and insights into clinical trials. Dr. Kantarjian’s extensive experience and contributions to leukemia research make him a vital source of information for those interested in hematologic oncology.

Follow Dr. Hagop Kantarjian on X/Twitter to stay updated with his latest research and insights on leukemia and other hematological malignancies.

About Hagop Kantarjian

Hagop Kantarjian is the professor and chair of the Department of Leukemia at The University of Texas MD Anderson Cancer Center, where he also serves as the Samsung Distinguished Leukemia Chair in Cancer Medicine. Dr. Kantarjian’s research focuses on translational-clinical developmental therapeutics in leukemia, spanning over four decades.

His contributions include advancements in chronic myeloid leukemia treatment, such as tyrosine kinase inhibitors like imatinib, dasatinib, nilotinib, and bosutinib. Moreover, he has made discoveries in acute lymphocytic leukemia, myelodysplastic syndrome, and leukemias treatment, resulting in over 20 FDA-approved drugs.

While staying tuned for upcoming Oncoinfluencers, check out previous profiles on our website on influential voices in the oncology community.